Resistance among urinary tract pathogens collected in Europe during 2018.

[1]  P. Miotła,et al.  Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance—non-antibiotic approaches: a systemic review , 2019, Archives of Gynecology and Obstetrics.

[2]  M. Pucci,et al.  The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017 , 2019, bioRxiv.

[3]  P. Eckburg,et al.  Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects , 2019, Antimicrobial Agents and Chemotherapy.

[4]  A. Rubio,et al.  Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms , 2019, Antimicrobial Agents and Chemotherapy.

[5]  Ronald N. Jones,et al.  Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of β-lactamase Resistance Genes and Lineage Background in the United States , 2019, Open forum infectious diseases.

[6]  L. Leibovici,et al.  Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study , 2018, BMJ Open.

[7]  E. Concia,et al.  Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections , 2017, Journal of chemotherapy.

[8]  Linnea A. Polgreen,et al.  The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998–2011 , 2017, Open forum infectious diseases.

[9]  D. Talan,et al.  Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase–Producing Escherichia coli Infections in Patients with Pyelonephritis, United States , 2016, Emerging infectious diseases.

[10]  G. Eliopoulos,et al.  Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics , 2016, Antimicrobial Agents and Chemotherapy.

[11]  G. Peirano,et al.  The Role of Epidemic Resistance Plasmids and International High-Risk Clones in the Spread of Multidrug-Resistant Enterobacteriaceae , 2015, Clinical Microbiology Reviews.

[12]  S. Hultgren,et al.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options , 2015, Nature Reviews Microbiology.

[13]  O. Ergonul,et al.  Emerging Escherichia coli O25b/ST131 clone predicts treatment failure in urinary tract infections. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  B. Otlu,et al.  Oral Amoxicillin-Clavulanic Acid Treatment in Urinary Tract Infections Caused by Extended-Spectrum Beta-Lactamase–Producing Organisms , 2014, Jundishapur journal of microbiology.

[15]  N. Ahmed,et al.  Comparison of Etiological Agents and Resistance Patterns of the Pathogens Causing Community Acquired and Hospital Acquired Urinary Tract Infections , 2014, Journal of global infectious diseases.

[16]  A. Brolund.  Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective , 2014, Infection ecology & epidemiology.

[17]  K. Peck,et al.  Epidemiology of Ciprofloxacin Resistance and Its Relationship to Extended-Spectrum β-Lactamase Production in Proteus mirabilis Bacteremia , 2011, The Korean Journal of Internal Medicine.

[18]  R. Cantón,et al.  The CTX-M β-lactamase pandemic , 2006 .

[19]  J. Verhoef,et al.  Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997 , 2000, Antonie van Leeuwenhoek.